Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.37 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2887701 | 0.91 | HRH4 (0.44) | KMT2AOPRM1OPRD1ALDH1A1TDP1 | |
| SCHEMBL367835 | 0.78 | KMT2A (0.46) | KMT2AOPRM1OPRD1ALDH1A1TDP1 | |
| SCHEMBL2884300 | 0.78 | HRH3 (0.45) | PDK1 | |
| SCHEMBL2088176 | 0.74 | KMT2A (0.56) | KMT2AOPRM1OPRD1ALDH1A1GAA | |
| SCHEMBL5421730 | 0.74 | POLB (0.50) | KMT2AEGLN1BCHEACHEHDAC6 | |
| SCHEMBL2419828 | 0.73 | ALDH1A1 (0.44) | KMT2AOPRM1OPRD1ALDH1A1TDP1 | |
| SCHEMBL3853097 | 0.70 | HCAR3 (0.43) | KMT2AOPRM1OPRD1ALDH1A1TDP1 | |
| SCHEMBL2421365 | 0.69 | KMT2A (0.51) | KMT2AOPRM1OPRD1ALDH1A1TDP1 | |
| SCHEMBL30444680 | 0.69 | HCAR2 (0.50) | KMT2AALDH1A1HRH4MEN1PDK1 | |
| SCHEMBL4061969 | 0.69 | NAPRT (0.50) | KMT2AALDH1A1L3MBTL1EGLN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846700-B2 | Heteroaryl quinazoline derivatives | MSD K.K. (JP) | 2014-09-30 | — | — | US | disclosed |
| EP-2221301-B1 | HETEROARYLOXY QUINAZOLINE DERIVATIVE | MSD KK (JP) | 2014-06-04 | — | — | EP | disclosed |
| US-20140011801-A1 | HETEROARYL QUINAZOLINE DERIVATIVES | MSD K.K. (JP) | 2014-01-09 | — | — | US | disclosed |
| US-20120270856-A1 | HETEROARYLOXY QUINAZOLINE DERIVATIVES | IINO TOMOHARU (JP) | 2012-10-25 | — | — | US | disclosed |
| US-8232284-B2 | Heteroaryloxy quinazoline derivative | MSD K. K. (JP) | 2012-07-31 | — | — | US | disclosed |
| US-20100249146-A1 | HETEROARYLOXY QUINAZOLINE DERIVATIVE | MSD K.K. (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2221301-A1 | HETEROARYLOXY QUINAZOLINE DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249146-A1 | HETEROARYLOXY QUINAZOLINE DERIVATIVE | GCKR, GCK, KHK | KMT2A 2220/4885OPRM1 1653/4885OPRD1 949/4885 |
| US-20140011801-A1 | HETEROARYL QUINAZOLINE DERIVATIVES | GCK, GCKR, KHK | KMT2A 1791/4885OPRM1 1701/4885OPRD1 970/4885 |
| US-20120270856-A1 | HETEROARYLOXY QUINAZOLINE DERIVATIVES | GCK, GCKR, KHK | KMT2A 2171/4885OPRM1 1660/4885OPRD1 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.